| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | May 30, 1989 |
| PATENT TITLE |
16,17 acetals of pregnane derivatives and pharmaceutical compositions containing them |
| PATENT ABSTRACT |
A compound exhibiting anti-inflammatory properties having the formula ##STR1## in which X is H, Hal or CH.sub.3 COO--; R.sub.1 is CH.sub.3 (CH.sub.2).sub.2 CH--; and R.sub.2 and R.sub.3 are separately H or Hal; and a pharmaceutical composition containing the same. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | January 2, 1987 |
| PATENT FOREIGN APPLICATION PRIORITY DATA | This data is not available for free |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
I claim: 1. A compound according to the formula ##STR3## in which X is H, Hal or CH.sub.3 COO-; R.sub.1 is CU.sub.3 (CH.sub.2).sub.2 CH-; and R.sub.2 and R.sub.3 are separately H or Hal. 2. A pharmaceutical composition having anti-inflammatory properties comprising as the active ingredient an effective amount of a compound according to claim 1 together with a pharmaceutically acceptable carrier. 3. A method of treating inflammatory conditions which comprises administering to a patent an anti-inflammatory effective amount of a composition according to claim 2. 4. 9.alpha.-Fluoro-21-chloro-16.al pha.,17.beta.-butylidenedioxy-11.beta.-hydroxypregna-4-ene-3,20-dione. 5. A pharmaceutical composition having antiinflammatory properties comprising as the active ingredient an effective amount of the compound according to claim 4 together with a pharmaceutically acceptable carrier. 6. A method of treating inflammatory conditions which comprises administering to a patient an anti-inflammatory effective amount of a composition according to claim 5. 7. 6.alpha.-Fluoro-16.alpha.,17.be ta.-butylidenedioxy-11.alpha.,21-dihydroxypregna-4-ene-3,20-dione. 8. A pharmaceutical composition having antiinflammatory properties comprising as the active ingredient an effective amount to the compound according to claim 7 together with a pharmaceutically acceptable carrier. 9. A method of treating inflammatory conditions which comprises administering to a patient an anti-inflammatory effective amount of a composition according to claim 8. 10. 9.alpha.-fluoro-16.alpha.,17.a lpha.-butylidenedioxy-11.beta.,21-dihydroxypregna-4-ene-3,20-dione. 11. A pharmaceutical composition having anti-inflammatory properties comprising as the active ingredient an effective amount of the compound according to claim 10 together with a pharmaceutically acceptable carrier. 12. A method of treating inflammatory conditions which comprises administering to a patient an anti-inflammatory effective amount of a composition according to claim 11. 13. 6.alpha.-Fluoro-9.alpha.-chloro -16.alpha.,17.beta.-butylidenedioxy-11.beta.-hydroxy, 21-acetoxy-pregna-4-ene-3,20-dione. 14. A pharmaceutical composition having antiinflammatory properties comprising as the active ingredient an effective amount of the compound according to claim 13 together with a pharmaceutically acceptable carrier. 15. A method of treating inflammatory conditions which comprises administering to a patient an anti-inflammatory effective amount of a composition according to claim 14. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
The following non limiting examples further illustrate the invention. The designation "A epimer" or "B epimer" is made according to U.S. Pat. No. 3,928,326 and the epimer ratio was determined by HPLC using a reversed phase RP-18 column, eluting with 40% acetonitrile. |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |